The Didi Chuxing, Tencent and Taikang Life-backed automotive sales services provider had originally targeted $300m and then $150m.

Biopharmaceutical company Liquidia Technologies, which counts PPD and Siemens as investors, floated in the middle of its range.

The Tasly-backed hepatitis C drug developer priced its shares in the middle of their range and is set to float at the start of next month.

The Eon-backed fuel cell system producer priced the offering at the top of its range, having previously raised more than $1.3bn in funding.

The China-based group buying service is set to float at the top of its range today, with Tencent remaining its largest investor.

The Johns Hopkins-backed antibody developer floated above its range and has seen its stock almost double in price.

The UC Investment Office-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.

The SR One-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.

The Roche-backed antibody developer floated above its range and has seen its stock almost double in price.

UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.